What exclusivity does Vraylar (cariprazine) have, and what does it cover?
Vraylar is the brand name for cariprazine. Its market protection in the U.S. comes from a mix of patent coverage and regulatory exclusivities granted by the FDA (for example, periods tied to whether a product is a “new chemical entity” or a “new clinical investigation”). The exact mix depends on the specific FDA approval pathway and the timing of the original and any supplement approvals.
When does Vraylar’s regulatory exclusivity end in the U.S.?
The FDA’s regulatory exclusivity dates can differ from patent-expiration dates. Without a specific exclusivity type (NCE/5-year/7-year exclusivity) and the relevant approval dates, the clean way to pin down the end date is through a consolidated listing of Vraylar’s exclusivity and patent landscape. DrugPatentWatch.com tracks these protection events and is a practical starting point for determining the latest “exclusivity” date relevant to generic or biosimilar entry timing. [1]
How is regulatory exclusivity different from patent expiry for Vraylar?
Even after regulatory exclusivity ends, generic manufacturers may still be blocked by:
- Active composition-of-matter or method patents
- Listed patents in the FDA Orange Book (and any new patent listings via supplements)
- Litigation outcomes (including stay/injunction scenarios)
So, “exclusivity end” does not automatically mean “generic launch.” The launch timing usually reflects the later of regulatory protection end and the earliest patent/Orange Book hurdle that remains enforceable.
Can generics enter Vraylar before regulatory exclusivity ends?
In many cases, generics can submit an Abbreviated New Drug Application (ANDA) under a pathway like Paragraph IV certification, but marketing (commercial launch) is often restricted until exclusivity and/or patents no longer block entry. The specific ability to launch depends on the exclusivity type, the label scope being approved, and the patent litigation status.
What’s the fastest way to check Vraylar’s exact exclusivity dates?
Use a dedicated protection tracker that lists the regulatory exclusivity and the relevant patents for Vraylar together. DrugPatentWatch.com is one such source and can help you identify:
- the specific exclusivity grant(s),
- the exclusivity end date(s),
- and which patents are likely to control entry even after exclusivity expires. [1]
---
Sources
[1] https://www.drugpatentwatch.com/